Sentences with phrase «thoracic oncology»

The IASLC Tobacco Control and Smoking Cessation committee published a commentary in the IASLC Journal of Thoracic Oncology in the April, 2014 edition which offers a worldwide perspective on the information available and a context for medical practitioners to communicate with their patients.

The authors presented the results of these and other studies on December 9 at the Chicago Multi ¬ disciplinary Symposium in Thoracic Oncology in Illinois, and their findings paint a bleak picture for Dunn County and its 3,000 inhabitants.

Margaret Watkins held a benefit concert in memory of her husband to support the UNC Lineberger Thoracic Oncology Program.

«It's a sign of the times,» says Alice Shaw, director of thoracic oncology at Massachusetts General Hospital in Boston.

Two leading international lung cancer organizations, the International Association for the Study of Lung Cancer (IASLC) and British Thoracic Oncology Group (BTOG), are partnering to use the BTOG annual conference, held January 24 - 26, 2018 in Dublin, Ireland, to highlight and inform about changes to the international system of staging lung cancer.

British Thoracic Oncology Group was established in 2002.

The pair established the James W. and Kay J. Mann Fund for Thoracic Oncology Research as a part of the UNC Lineberger Seed Grant Program, which invests in the advancement of innovative, early - stage ideas in cancer research.

Alexander Drilon, MD Clinical Director, Developmental Therapeutics Assistant Attending Physician Thoracic Oncology Service Memorial Sloan Kettering Cancer Center New York, NY

«This study demonstrates the value of testing lung cancer tissue for an ALK rearrangement, and it underscores the potential of cancer genomics to target cancer treatments to each patient,» says the study's senior author, Pasi A. Jänne, MD, PhD, who is the director of the Lowe Center for Thoracic Oncology of Dana - Farber.

The booklet has been endorsed by the International Association for the Study of Lung Cancer and the International Thoracic Oncology Nursing Forum.

International Thoracic Oncology Nurses Forum / National Lung Cancer Forum for Nurses (ITONF / NLCFN): $ 30.00 (Allied Health Professional Membership) includes online JTO only

As patient advocate at the University of Colorado Cancer Center Lung Cancer Specialized Program of Research Excellence (SPORE), Freeman - Daily spoke with Robert C. Doebele, MD, PhD, CU Lung SPORE PI and Director of CU Cancer Center Thoracic Oncology Research Initiative, and in partnership, CU, the Global ROS1 Initiative and the Bonnie J. Addario Lung Cancer Foundation created a program in which patients could donate cancer tissue for use in establishing cell lines.

Balazs Halmos, MD Professor of Clinical Medicine Section Chief Thoracic Oncology and Director Clinical Cancer Genomics Albert Einstein College of Medicine Einstein Montefiore Cancer Center

Two complementary papers published back - to - back recently in the journal Radiotherapy and Oncology and the Journal of Thoracic Oncology outline the treatment success at Wake Forest Baptist.

A joint study by University of Colorado Cancer Center and Memorial Sloan Kettering Cancer Center published in the Journal of Thoracic Oncology shows two distinct causes of HER2 activation in lung cancer: mutation of the gene and amplification of the gene.

«The authors plan to bridge this gap with a multidisciplinary team of thoracic oncology experts and system engineers,» he said.

The IASLC is the only global multidisciplinary organization of experts and leaders in thoracic oncology who are solely dedicated to conquering lung cancer and other thoracic malignancies throughout the world.

What: The Second Edition of the IASLC Staging Manual in Thoracic Oncology reports on the latest revisions of the tumor, node and metastasis (TNM) classifications of thoracic malignancies, namely, lung cancer, malignant pleural mesothelioma, carcinoma of the esophagus and of the esophago - gastric junction and thymic epithelial tumors.

The Journal of Thoracic Oncology invites IASLC 17th World Conference on Lung Cancer (WCLC) attendees to meet with the Editor - in - Chief, Alex A. Adjei, MD, PhD, and the Managing Editor, Mary Todd.

Jim came under the care of Dr. Patricia Rivera, co-director of UNC's Multidisciplinary Thoracic Oncology Program and cardiothoracic surgeon, Dr. Benjamin Haithcock.

Lugano, Switzerland, 21 April 2017 — The European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) have announced that the 2017 Heine H. Hansen (HHH) Award will be given to Rafal Dziadziuszko, a global leader in clinical thoracic oncology.

Fellows are non-voting members, entitled to most other IASLC benefits, including: Journal of Thoracic Oncology Subscription (Online only); Free CME Opportunities; Discounted registration to IASLC meetings, workshops and webinars; Eligibility for Fellowship and Travel Awards.

e-Cigarettes and Cancer Patients - Journal of Thoracic Oncology Article e-Cigarettes are a rapidly growing market and there is limited infomation on the long - term impact of these devices.

Lung Cancer is approached at Penn in a multidisciplinary fashion from both the clinical and research perspective using the infrastructure of the Abramson Cancer Center's interdisciplinary Thoracic Oncology Program (ITOP).

Throughout his career, he has worked in diagnostic histopathology with a special interest in Thoracic Pathology, but has always maintained close links with the clinical practice of thoracic medicine, especially thoracic oncology.

Dr. Engelman is the principal investigator of his own laboratory at the Massachusetts General Hospital (MGH) Cancer Center, the director of thoracic oncology at MGH and the director of molecular therapeutics at the MGH Cancer Center.

Mark G. Kris, MD Attending Physician, Thoracic Oncology Service Memorial Sloan Kettering Cancer Center New York, NY

Director, Thoracic Oncology Program Interim Director, Johns Hopkins Kimmel Cancer Center at Bayview Associate Professor of Oncology Sidney Kimmel Comprehensive Cancer Center Johns Hopkins School of Medicine Baltimore, MD

Jim and Kay decided to earmark their seed grant gift to thoracic cancer research and created The James W. and Kay J. Mann Fund for Thoracic Oncology Research.

In 2011, the Journal for Thoracic Oncology published the «International Association for the Study of Lung Cancer / American Thoracic Society / European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma,» issued by a multidisciplinary team of lung cancer specialists.

International Thoracic Oncology Nurses Forum / National Lung Cancer Forum for Nurses (ITONF / NLCFN): $ 30.00 (Allied Health Professional Membership) includes online JTO only Details

Gerard A. Silvestri, M.D., M.S., a lung cancer pulmonologist at the MUSC Hollings Cancer Center who holds the George C. and Margaret M. Hillenbrand Endowed Chair in thoracic oncology, led the study.

Dr. Jennifer S. Temel, clinical director of thoracic oncology at Massachusetts General Hospital, alluded to the emerging research on immunotherapy in a presentation to palliative care and hospice clinicians in February.

Often, it is not diagnosed until at a late stage, when many tumors have already formed,» said principal investigator Lucian Chirieac, MD, a thoracic oncology pathologist in the Department of Pathology at BWH and associate professor at Harvard Medical School.

Results published in the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer (IASLC), show that low preoperative levels of squamous cell carcinoma antigen in the serum or either absence of tumor invasion into the pleura (the space between the lungs and chest wall) or tumor vasculature are independent prognostic factors for patients with any stage of p - SCC.

These results are among the best in the field, offering a lot of hope to people with ALK - positive lung cancer,» says D. Ross Camidge, MD, PhD, director of thoracic oncology at the University of Colorado Cancer Center and the trial's principal investigator.

Alexander Drilon, MD, Assistant Attending Physician in the Developmental Therapeutics Clinic and the Thoracic Oncology Service, will report results from the international phase I STARTRK - 1 and STARTRK - 2 clinical trials, which assessed entrectinib as a treatment for patients with advanced solid tumors harboring gene rearrangements and of which he is principal investigator at MSK.

Results published in the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer (IASLC), show that the incremental cost - effectiveness ratio (ICER) for testing and waiting for results compared to treatment with chemotherapy with no testing was $ 136,000 per quality - adjusted life year (QALY) gained, which is thought to provide a good value from a societal prospective.

Inhibiting HMGB1 dramatically reduced malignant mesothelioma growth in mice and significantly improved survival of treated animals,» said Dr. Haining Yang, PhD, an associate professor in the Thoracic Oncology Program at the UH Cancer Center.

The September issue of the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer (IASLC), reports that the mutation status concordance between tumor and matched plasma for 652 patients that had results for both was 94 % (95 % CI 92 - 96) with a sensitivity of 66 % (CI 56 - 75) and specificity of 100 % (CI 99 - 100).

«Pembrolizumab is a PD - 1 antibody approved for second line treatment of patients with advanced non-small-cell lung cancer (NSCLC) and PD - L1 expression in their tumour cells,» said lead author Professor Martin Reck, chief oncology physician, Department of Thoracic Oncology, Lung Clinic Grosshansdorf, Germany.

Working with collaborators, Dr. Yang and Dr. Michele Carbone, MD, PhD, director of the UH Cancer Center's Thoracic Oncology Program, found that at least some of the so far unknown anti-tumor activity of aspirin is through preventing HMBG1 activity.

Commenting on the trial, Dr Alice Shaw, director of thoracic oncology at the Massachusetts General Hospital Cancer Centre in Boston, US, said: «This is the first randomised study to examine how a second generation ALK inhibitor compares to standard second line chemotherapy in ALK positive patients who failed the standard first line therapy, which currently is crizotinib.»

In his role as the director of thoracic oncology at MGH, he directs the research program of the thoracic oncology team.

«The team recently published their results in the Journal of Thoracic Oncology and found that the procedure was well tolerated at all ages — even in those patients aged over 80 years old.

Their results are published in the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer (IASLC).